Hello! I'm your financial news analysis assistant. The article from "Yiyao" is incredibly insightful; it connects three seemingly unrelated events happening in the United States, China, and Boston into a clear narrative: the global pharmaceutical industry is experiencing a fundamental shift in pricing power.
In the past, pharmaceutical companies would say, "We spent so much on research and development, so we can charge this much," and everyone just accepted it. But now, governments, health insurance agencies, and insurance companies (the people who pay for the drugs) are stepping forward and saying, "No, we will set the rules. We will decide how much your product is worth."
Let me break down this complex news into five easy-to-understand points to help you grasp this major upheaval in the pharmaceutical industry:
---
1. Core Summary: Who Is Taking Control of the Conversation?
In a nutshell: For the past thirty years, the global pharmaceutical industry has thrived on the high subsidies the United States provided for global research and development. Now, the U.S., China, and the payment systems behind them (insurance companies and evaluation agencies) are all working together to shift the power from pharmaceutical companies to the payers.
Three Key Signals:
- The U.S. (Washington): Using tariffs as a tool, the U.S. is forcing pharmaceutical companies to sign "Most-Favored-Nation" (MFN) agreements. This means that the price of a drug sold in the U.S. must be the same as its price in Switzerland; companies can no longer profit from inflated prices.
- China (Beijing): China has split its healthcare system into two parts: the basic healthcare insurance, which focuses on affordability, and the commercial insurance system, which covers more expensive, innovative drugs.
- The Market (Boston): A newly approved drug for a rare disease saw its stock price drop even before it was sold, simply because the price was considered too high. This shows that the market no longer only cares about the quality of the drug but also who can afford it.
Conclusion: The payers (governments, health insurance, and insurance companies) are no longer passively accepting drug prices; they are actively setting them.
---
2. In-Depth Analysis: Three Different Approaches, All Leading to the Same Outcome
2.1 The U.S. Approach: Tariffs as a Weapon, Agreements as a Shield
Simple Explanation: The U.S. government used to try to lower drug prices but was often stopped by courts or resisted by pharmaceutical companies. The Trump administration adopted a tougher approach: "Either build a factory in the U.S. or lower your prices, or we’ll impose a 100% tariff."
- How It Works: The government introduced the MFN agreement, ensuring that U.S. drug prices are in line with the lowest prices in other developed countries like Switzerland and Japan. This means U.S. drug prices can no longer be significantly higher.
- Result: Giants like Pfizer, Novartis, and BeiGene were forced to sign these agreements, covering nearly 90% of the U.S. branded drug market.
- Implication: The U.S. is no longer the one bearing the brunt of high drug prices. The shift is from the U.S. paying for global research and development to global price competition, which is a significant blow to companies that rely on high profits in the U.S.
2.2 The Chinese Approach: Splitting the Healthcare System
Simple Explanation: China’s healthcare system previously had a hidden barrier: expensive drugs (such as CAR-T therapies and new Alzheimer’s drugs) were not covered by basic insurance. Now, the National Healthcare Security Administration has created two separate lists:
- Basic Healthcare Insurance: Focuses on affordability, with 114 new drugs added to the list.
- Commercial Health Insurance: Targets innovative drugs that are expensive but still needed, providing a way for patients to access them.
- Key Benefit: Hospitals and doctors no longer face penalties for prescribing these expensive drugs, solving the problem of them not being widely available.
- Implication: China is no longer trying to cover all expensive drugs with basic insurance; instead, it uses a multi-tiered payment system, which is a relatively mature model globally.
2.3 The Boston Example: Why Did the Stock Price Drop for a $310,000 Drug?
Simple Explanation: A company called Scholar Rock developed a new drug for spinal muscular atrophy (SMA) that was approved at a price of $310,000 per year. Despite being a breakthrough, its stock price dropped by 6.4%.
- Reason: The Value Assessment Agency (ICER) calculated the drug’s value at $30,000 per year before approval. Insurance companies and health insurance agencies refused to pay that much.
- Market Reaction: Investors realized that, although the drug is effective, few people could afford it. Therefore, approval is no longer the end of the story; pricing negotiations begin much earlier.
---
3. Major Changes in the Industry Logic: From High Prices to High Sales Volumes
These three developments together have completely changed the way pharmaceutical companies make money.
Old Formula: Profit = High Price × Small Patient Group (rare diseases) × Short Treatment Period
- Previously: As long as a drug was new and scarce, even if it only affected 10,000 patients, it could still generate significant profits.
New Formula: Profit = Reasonable Price × Large Patient Group × Long Treatment Period
- Now: Prices are being capped by governments and health insurance, so companies can no longer rely on scarcity to make huge profits.
- New Approach: The focus is on diseases with many patients and long treatment periods, such as diabetes, hypertension, obesity, and Alzheimer’s.
- For example, GLP-1 drugs for weight loss and diabetes have seen their prices cut by 65%, but since they are used by hundreds of millions of people worldwide, the market remains large.
- Conclusion: The future’s blockbuster drugs will not be expensive, rare, and hard-to-access ones; they will be affordable and widely used.
4. China’s Changing Role: From a Price Lowland to a Rulemaker
China’s role in this global restructuring is both subtle and significant:
- No Longer Just a Source of Low-Price Drugs: Chinese pharmaceutical companies like BeiGene are adapting to both Chinese and U.S. payment rules, selling drugs in China at competitive prices and signing MFN agreements in the U.S.
- China as a Rule Setter: China’s centralized procurement and dual-list system are more systematic and effective than the U.S. tariffs.
- Potential Impact: The prices set by China’s commercial insurance system may become a global reference. Chinese companies may have to adjust their prices overseas based on these domestic standards.
- Opportunities: Drugs that are priced too high in the U.S. due to MFN agreements or market pressure may find new markets in China. At the same time, Chinese innovative drugs (like KRAS inhibitors) are emerging to fill the gap.
- Conclusion: Chinese companies are no longer just selling drugs; they are also understanding how to navigate the complex payment systems.
---
5. A Guide for Ordinary People and Industry Professionals
What does all this mean for you, whether you’re a stock investor, a patient, or a professional in the pharmaceutical industry?
- For Investors: Stop focusing solely on drug approvals; consider the payment pathways set by governments and insurance companies. Be cautious of overestimating the success of newly approved drugs, as their prices may be negotiated later.
- For Patients and Families: High-priced drugs are becoming more accessible in China due to the commercial insurance system. However, basic insurance will cover only the most essential treatments, so a combination of basic and commercial insurance is needed.
- For Industry Professionals: Research and development should focus on diseases with large patient populations. Sales strategies need to target health insurance agencies and hospitals. Pricing must be carefully calculated before a drug is launched.
---
Conclusion: A Mathematical Problem, Also a Systemic Issue
Consider the example of a child weighing 33-66 pounds who needs a drug costing $310,000 per year:
- The White House wants to know the price in Switzerland.
- The health insurance agency says it’s too expensive and suggests including it in the commercial insurance list with negotiated prices.
- The evaluation agency says the drug is only worth $30,000 based on its effectiveness.
This is not about right or wrong; the rules of the game have changed. The pharmaceutical industry used to profit from information asymmetry and scarcity, but now it relies on efficiency and scale. The payers have regained control of pricing. Only companies that can demonstrate the value of their drugs will survive this transformation.
Thank you for reading! If you have any further questions, feel free to ask.